Broad Institute

OCTOBER 11, 2023

The drugs work by blocking a protein, PD-1 — which helps keep immune responses in check — and stimulating the immune system to attack tumors. The team studied the immune response to CRISPR and designed a new technology that they published in 2021 — a way of removing immune-triggering molecules from CRISPR-edited cells.

Research 137

Research Immune Response Clinical Trials Therapies 137

Broad Institute

JULY 11, 2024

Treatment with mIDH1 blockers unearths these remnants, triggering an immune response against the tumor cells. IDH1 normally facilitates the activity of enzymes called demethylases, which remove chemical flags called methylation marks from DNA, allowing genes to be transcribed into RNA.

Treatment 72

Treatment Immune Response Virus Drugs 72

Broad Institute

JUNE 27, 2024

Unlike gene editing, this “epigenetic” editing does not modify the underlying DNA sequence, but it should switch the gene off permanently, which means that this could be a one-time treatment. Like Cas9, ZFPs can serve as guide proteins to direct the tool to a target site in DNA.

Disease 142

Disease Therapies Engineering Clinical Trials 142

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

PLOS: DNA Science

MAY 16, 2024

Many of the links below are to some of the 100+ DNA Science posts that I wrote during the pandemic. • identifies parts of the virus to target to provoke an immune response from a vaccine. After sequencing, artificial intelligence adds context to RNA and DNA sequences through comparisons to others.

Virus 98

Virus DNA RNA Laboratories 98

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. In bacteria , cGAS-like cyclases are central parts of the CBASS immune response.

RNA 59

RNA Immune Response DNA Molecular Biology 59

Drug Target Review

OCTOBER 4, 2023

2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. Florian S, Mitchison TJ. Chang, P. &

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

JANUARY 15, 2024

Unlike almost every other cell type (except B cells), T cells do not have the exact same chromosomal DNA sequences as other cells in the body. To be therapeutically useful, antigenic peptides must be presented in a way that allows immune responses to destroy cancer cells without causing unacceptable damage to healthy tissue.

Engineering 110

Engineering DNA Virus Immune Response 110

Codon

AUGUST 27, 2024

Allison Berke makes the case for real-time DNA sequencing and AI tools to detect pathogens before they spread widely. Reading DNA The first step in detecting a novel pathogen is recognizing it as an anomaly amidst a noisy background of other material. After copying the DNA to form a big pool, each piece is sequenced.

DNA 83

DNA Laboratories Hospitals Virus 83

PLOS: DNA Science

OCTOBER 19, 2023

Last week DNA Science covered a setback in a clinical trial of a gene therapy for Duchenne muscular dystrophy (DMD). It aims to correct the faulty instructions at the DNA level, straightforward, at least conceptually, because mutations are deletions, of part or all of the gene. That’s not the case for ALS.

Therapies 111

Therapies FDA Clinical Trials DNA 111

Drug Target Review

MAY 14, 2024

Since cancer cells are under chronic stimulation of ER stress, the polypeptides cannot activate innate immune sensors in cancer cells even upon the polypeptide treatment. Which natural agonists impede the activation of intracellular DNA sensors in APCs, and what challenges do they pose?

Engineering 59

Engineering Immune Response FDA Approval Clinical Trials 59

Drug Target Review

JUNE 6, 2023

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

The Pharma Data

DECEMBER 20, 2020

SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . Source link.

Clinical Trials 52

Clinical Trials Vaccine Pharma Companies Trials 52

PLOS: DNA Science

OCTOBER 3, 2024

The idea to redirect an immune response against a pathogen to fight cancer goes back to 1891, when Manhattan bone surgeon William Coley became intrigued by a man’s neck tumor that melted away after he contracted a nasty Streptococcus skin infection. .’” The fishy strategy is both fast and patient-specific.

Vaccine 52

Vaccine Immune Response DNA Treatment 52

Drug Target Review

APRIL 26, 2023

Gene-editing methods allow researchers to modify DNA, resulting in alterations in physical characteristics such as eye colour and susceptibility to diseases. To achieve this, scientists utilise various technologies that function similarly to scissors, precisely cutting the DNA at a particular location.

RNA 98

RNA Medical Schools Engineering DNA 98

Drug Target Review

JUNE 9, 2023

An antigen is a protein that can induce an immune response in the body. While tumour cells share a majority of their DNA with healthy cells, they also carry numerous unique mutations. This first T-cell therapy product targets a common shared neoantigen found in patients with solid tumours.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Codon

FEBRUARY 13, 2024

Such contaminants could have the same toxic effects as the bacterial infection, or provoke a severe immune response in the patient, and therefore the phage mixtures must go through extensive purification and testing procedures. This process would begin by taking a sample of bacteria from the patient and sequencing its DNA.

Therapies 117

Therapies DNA Virus Clinical Trials 117

PerkinElmer

MAY 6, 2022

One approach currently being explored involves stimulating innate immune response pathways. For example, the STimulator of InterferoN Genes (STING) pathway, which is known to play a critical role in innate immunity in response to viral and bacterial DNA, has also been shown to promote anti-tumor immune responses.

Immune Response 52

Immune Response DNA Clinical Trials Engineering 52

Broad Institute

AUGUST 11, 2022

Microbial armory In an earlier study, the researchers scanned data on the DNA sequences of hundreds of thousands of bacteria and archaea, which revealed several thousand genes harboring signatures of microbial defense. Most known bacterial defense systems work by sensing viral DNA or RNA, or cellular stress due to the infection.

DNA 52

DNA Virus Immune Response Bioinformatics 52

Codon

SEPTEMBER 29, 2024

mRNA was the intermediate stage between DNA and protein, a dynamic entity that shifted depending on the second-to-second needs of the cell, able to point out if a cell was cancerous or stressed, what kind of cell it was, and so on. Collections of mRNA have been understood as a proxy for cell states for decades.

Engineering 132

Engineering Virus DNA Therapies 132

Drug Target Review

SEPTEMBER 8, 2023

The cell’s nucleus, containing compacted DNA, is centrally positioned within the cell. It didn’t have the tools that are important for nuclear receptors, namely the ability to interact with DNA and the ability to translocate from the cytoplasm to the nucleus,” says Cheroutre.

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.

DNA 52

DNA Immune Response Therapies Treatment 52

Broad Institute

AUGUST 7, 2023

Related people Paul Blainey Nir Hacohen A signaling protein known as STING is a critical player in the human immune system, detecting signs of danger within cells and then activating a variety of defense mechanisms.

Regulations 91

Regulations Clinical Trials Engineering DNA 91

Drug Target Review

OCTOBER 26, 2023

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications.

Engineering 105

Engineering Virus Therapies Immune Response 105

Drug Target Review

NOVEMBER 6, 2023

For example, combining IO agents with ADCs to mount a two-pronged attack against cancer by activating an anti-cancer immune response and directly killing cancer cells may drive stronger and more durable responses in the clinic.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

PLOS: DNA Science

JANUARY 4, 2024

.” CRISPRs are short DNA sequences, peppered with repeats, that latch onto DNA-cutting enzymes, commandeering and directing them to snip certain parts of a chromosome. The microbes deploy them to dismantle the genetic material of infecting viruses, a little like an immune response.

FDA Approval 52

FDA Approval DNA Therapies Clinical Trials 52

Conversations in Drug Development Trends

JUNE 21, 2024

Although there are a range of efficacies across different tumor types that require a greater understanding, the use of circulating tumor DNA profiles holds promise for personalized treatment strategies that better target the drug for the patient, potentially revolutionizing how ADCs are deployed in clinical practice.

Clinical Trials 64

Clinical Trials Therapies Clinical Research Immune Response 64

PLOS: DNA Science

SEPTEMBER 5, 2024

This removes the cancer’s blocking of the immune response, so that T cells can fight the cancer. Keytruda’s classification based on mechanism, rather than its structure, is immune checkpoint inhibitor. Analyzing DNA patterns using AI may replace time-consuming process DNA and genomic sequencing tests, Yu said.

Treatment 52

Treatment FDA Approval DNA Small Molecule 52

Codon

DECEMBER 12, 2024

DNA and RNA molecules are also built from exclusively right-handed nucleic acids. Across the tree of life, organisms strictly require exactly one of the two chiral forms of their molecular building blocks — amino acids, nucleotides of RNA and DNA. 4 As far as we know, right-handed proteins never occur naturally.

DNA 81

DNA RNA Vaccine Virus 81

Drug Target Review

APRIL 3, 2024

Everything started in school with an experiment on isolating DNA from bananas. Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences.

Science 105

Science Clinical Development Treatment DNA 105

DrugBank

MAY 15, 2024

In the early 20th century, the discovery process was largely random , focused on cytotoxic agents that kill cells by disrupting key cellular functions like DNA replication. A Historical Perspective on Drug Development The history of drug discovery gives us great insights into the evolution from hit-or-miss strategies to precise interventions.

Small Molecule 82

Small Molecule Molecular Biology Drugs Disease 82

Drug Target Review

DECEMBER 5, 2024

2 Structure and function of AAV capsids in gene therapy Wild-type AAV is composed of a protein shell (capsid) that contains a single-stranded DNA genome encoding proteins involved in viral replication, structure and assembly. Therefore, vectors based on these serotypes may enable targeted gene delivery and optimal transduction efficiency.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

JANUARY 18, 2021

Next Generation AAVs enhance gene therapies by increasing transduction efficiency and specificity while reducing immune responses and cost. Use of AAVnerGene capsid library provided to Neurophth for ophthalmic gene therapy. WUHAN, China and NEWARK, DE. , a subsidiary of Wuhan Neurophth Biotechnology Ltd.

Therapies 52

Therapies Immune Response DNA Treatment 52

Drug Target Review

OCTOBER 2, 2024

While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies. As with all CGTs, safety concerns, particularly related to immune responses and long-term effects, are crucial in cardiology. Allogeneic cell therapies must avoid immune rejection.

Therapies 98

Therapies Disease Engineering RNA 98

LifeSciVC

JULY 1, 2024

The central dogma of molecular biology is that information generally (with few exceptions) flows from DNA to RNA to Protein. Build your social immunity. The adaptive immune response identifies and responds to highly specific antigens associated with infections and cancer. Remember life’s Central Dogma.

Science 80

Science Immune Response Molecular Biology RNA 80

The Pharma Data

NOVEMBER 18, 2020

.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. ” Presentation number: 397P / Poster: ID 680. Additional information can be found at www.obipharma.com. Forward-Looking Statements.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

AUGUST 6, 2020

Early clinical results showed AstraZeneca’s candidate, AZD1222, triggered both antibody and T-cell immune responses. In addition, Inovio previously teamed up with Beijing Advaccine Biotechnology for work on its DNA vaccine candidate, INO-4800. The vaccine was moved into phase 2/3 in May.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52